Design Therapeutics (DSGN) Cash & Equivalents (2020 - 2026)

Design Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 6.56% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $12.8 million (down 6.56% YoY), while the FY2025 annual figure was $16.9 million, down 25.29% from the prior year.
• Cash & Equivalents came in at $12.8 million for Q1 2026 at Design Therapeutics, down from $16.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $287.3 million in Q1 2022 to a low of $12.8 million in Q1 2026.
• A 5-year average of $46.3 million and a median of $27.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 91.12% in 2022 and jumped 68.03% in 2024, its largest moves.
• Design Therapeutics' Cash & Equivalents stood at $26.5 million in 2022, then decreased by 20.0% to $21.2 million in 2023, then grew by 6.43% to $22.6 million in 2024, then decreased by 25.29% to $16.9 million in 2025, then decreased by 24.24% to $12.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $12.8 million, $16.9 million, and $15.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison